The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

				OMB APPROVAL
UNI		on, D.C. 20549	IGE COMMISSION	OMB 3235- Number: 0076
	FC Notice of Exempt	DRM D	ritios	Estimated average burden
	Notice of Exempt	Onening of Sect	liftes	hours per 4.00 response:
1. Issuer's Identity				
CIK (Filer ID Nu	nber) Previous Names	X None		Entity Type
0001427570			X Corporatio	n
Name of Issue	r		Limited Pa	ırtnership
OBALON THERAPEUTIC	S INC		Limited Li	ability Company
Jurisdiction o			General Pa	ırtnership
Incorporation/Organ	nization		Business T	rust
DELAWARE			Other (Spe	cify)
Year of Incorpora	tion/Organization			
Over Five Years Ago				
X Within Last Five Years (S	Specify Year) 2008			
Yet to Be Formed				
2. Principal Place of Busines	s and Contact Information			
Name	of Issuer			
OBALON THERAPEUTIC	S INC			
Street A	Address 1		Street Address 2	
5421 AVENIDA ENCINAS		SUITE F		
City	State/Province/Country	ZIP/Pos	talCode Phone Num	iber of Issuer
San Diego	CALIFORNIA	92008	760-795-6552	7
3. Related Persons				
Last Name	Fire	st Name	Middle Na	me
Rasdal	Andrew		ivituate i va	
Street Address 1		Address 2		
5421 Avenida Encinas	Ste. F			
City		vince/Country	ZIP/PostalC	Code
San Diego	CALIFORNIA	·	92008	
<b>Relationship:</b> X Executive		er		
Clarification of Response (if				
	ivecessaly).			
Last Name		st Name	Middle Na	me
Kamdar	Kim		Puloma	
Street Address 1		Address 2		
5421 Avenida Encinas	Ste. F	•		
City		vince/Country	ZIP/PostalC	Code
San Diego	CALIFORNIA		92008	

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Sampson	Douglas C.	
Street Address 1	Street Address 2	
5421 Avenida Encinas	Ste. F	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92008
<b>Relationship:</b> Executive Officer X	Director Promoter	
Clarification of Response (if Necessar	ry):	

Last Name	First Name		Middle Name
Stevenson	Sharon		
Street Address 1	Street Address 2		
5421 Avenida Encinas	Ste. F		
City	State/Province/Country		ZIP/PostalCode
San Diego	CALIFORNIA	92008	
<b>Relationship:</b> Executive Office	er X Director Promoter		
Clarification of Response (if Nece	essary):		

## 4. Industry Group

Electric Utilities

Oil & Gas

5. Issuer Size

Other Energy

Energy Conservation Environmental Services

Agriculture Banking & Financial Services Commercial Banking	Health Care X Biotechnology Health Insurance	Retailing Restaurants
Insurance Investing Investment Banking	Hospitals & Physicians Pharmaceuticals	Technology Computers Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as an investment company under the Investment Company Act of 1940?	Manufacturing Real Estate Commercial	Travel Airlines & Airports Lodging & Conventions
Yes No	Construction	Tourism & Travel Services
Other Banking & Financial Se	ervices REITS & Finance	Other Travel
Business Services Energy Coal Mining	Residential Other Real Estate	Other

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000

X Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable

# 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)		Rule 505 Rule 506 Securities Act Investment Co			
		Section 3(c)		Section 3(c)(9)	
		Section 3(c)(2		Section 3(c)(10)	
		Section 3(c)(3		Section 3(c)(11)	
		Section 3(c)(4	4) 5	Section 3(c)(12)	
		Section 3(c)(5	5) 5	Section 3(c)(13)	
		Section 3(c)(6	6) 5	Section 3(c)(14)	
		Section 3(c)(7	)		
7. Type of Filing					
X New Notice Date of F Amendment	First Sale 2012-02-24 F	irst Sale Yet to (	Occur		
8. Duration of Offering					
Does the Issuer intend thi	s offering to last more tha	n one year?	Yes X No		
9. Type(s) of Securities O	ffered (select all that appl	y)			
Equity X Debt X Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		her Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities		
		n, Warrant or	Other (desc	ribe)	
10. Business Combination	n Transaction				
Is this offering being mad a merger, acquisition or e		siness combinat	tion transactio	on, such as Yes X No	
Clarification of Response	(if Necessary):				
11. Minimum Investment					
Minimum investment acc	epted from any outside in	vestor \$0 USD			
12. Sales Compensation					
Recipient		Recipi	ent CRD Nur	nber X None	
(Associated) Broker or D	ealer X None	(Assoc	ciated) Broke	r or Dealer CRD Number X None	
	et Address 1			treet Address 2	
City		State/P	rovince/Cour	ntry	ZIP/Postal Code
State(s) of Solicitation (see Check "All States" or check		l States Fore	ign/non-US		
13. Offering and Sales An	nounts				
Total Offering Amount	\$1,500,000 USD or	Indefinite			
Total Amount Sold	\$1,500,000 USD				

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

#### 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

### \$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
OBALON THERAPEUTICS INC	/s/ Andrew Rasdal	Andrew Rasdal	President	2012-03-26

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.